Cryptococcal Meningitis

Positive Phase II Results Of Adjunctive Actimmune Presented

Published in TB and Outbreaks Week, January 15th, 2002

InterMune, Inc., announced positive results from its Phase II clinical trial investigating Actimmune (interferon (gamma)-1b) as adjunctive therapy to conventional antifungal treatment of cryptococcal meningitis, a life-threatening fungal infection of the central nervous system.

The current standard of care is treatment with amphotericin B (AmB) followed by fluconazole. The addition of Actimmune to the standard regimen showed a strong trend toward more rapid clearance of Cryptococcus fungus from cerebral spinal fluid (CSF), when compared with conventional antifungal therapy alone.

These data were presented December 18, 2001, at the 41st Annual...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB and Outbreaks Week

Source: TB and Outbreaks Week (2002-01-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry